This research says it did. Is it because the junction point lies with exons of both genes?
-
This research says it did. Is it because the junction point lies with exons of both genes?
-
Sure, you can still pick up chromosomal and other structural rearrangements with exome sequencing, just not 100% of the time. You're correct that the reason this worked was due to the genes rearranging and effectively merging in the genome. Because of that, the capture kit still got reads that mapped to the end of one or the other of the genes (with the remainder mappable to the other gene).
This would be in contrast to detecting fusion transcripts arising from neighboring genes being coexpressed and spliced together. Those sorts of situations wouldn't be detectable with exome sequencing. -
The answer is that it depends on:
- where fusion junction point lies (it is "well" inside an exon which should be 'captured' properly and both genes involved in fusion should captured properly),
- coverage of sequencing
Whole genome sequencing and RNA-seq are ones of the most used for finding fusion genes and/or translocations.Comment
-
Hi,Originally posted by ymc View Posthttp://www.ncbi.nlm.nih.gov/pubmed/23313954
This research says it did. Is it because the junction point lies with exons of both genes?
Have you detected fusions using Exome tumor data?
Thanks,
SachinComment
-
For anyone interested: They used dRanger (not publicly available) and Breakpointer in order to detect the fusion from exome data.Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment